AIDSVAX
AIDSVAX
AIDSVAX (/ˈeɪdzvæks/) is a vaccine developed with the aim of preventing HIV infection. It was the first HIV vaccine to be tested in large-scale clinical trials.
Etymology
The term "AIDSVAX" is a combination of "AIDS", an acronym for Acquired Immune Deficiency Syndrome, and "vax", a common abbreviation for vaccine.
History
AIDSVAX was developed by VaxGen, a biopharmaceutical company based in the United States. The vaccine was designed to stimulate an immune response to the gp120 protein, a component of the HIV virus.
Clinical Trials
The vaccine underwent several phases of clinical trials. The results of these trials, however, showed that AIDSVAX was not effective in preventing HIV infection. Despite these results, the trials provided valuable information for future HIV vaccine research.
Related Terms
External links
- Medical encyclopedia article on AIDSVAX
- Wikipedia's article - AIDSVAX
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski